Day: June 3, 2024

Ontex finalizes the divestment of its business in Pakistan

Written by Customer Service on . Posted in Mergers And Acquisitions.

Aalst, Belgium, June 3, 2024 – Ontex Group NV [EURONEXT: ONTEX], a leading international developer and producer of care products and solutions, announces that it has completed the divestment of its business in Pakistan to ASAIA Holding FZ. The transaction includes Ontex’s plant and business in Pakistan. Gustavo Calvo Paz, CEO of Ontex, said: “I am pleased that we closed this divestment, allowing us to strengthen our focus on our core retail brand and healthcare markets. I would like to thank the team in Pakistan for their contribution to our business. I wish them the very best as they write this new chapter together.” This divestment follows the divestment of the Mexican activities in February 2023 and the divestment of the Algerian activities in April 2024. The remaining activities for which Ontex is pursuing strategic options are...

Continue reading

BW Energy: Appraisal confirms material Hibiscus field reserve increase

Written by Customer Service on . Posted in Public Companies.

BW Energy: Appraisal confirms material Hibiscus field reserve increase Reference is made to the stock exchange notice by BW Energy on 20 May 2024 announcing a substantial oil discovery on the northern flank of the Hibiscus field. BW Energy has now concluded the drilling and the logging of the DHIBM-7P pilot well, confirming a substantial oil discovery with good reservoir quality and a material uplift to the Hibiscus area. The Company’s preliminary evaluation indicates an increase in Hibiscus gross recoverable reserves (mid-case) of approximately 8 million barrels of oil to 12 million barrels of oil. The Company plans to complete the well as a development well later in 2024. The DHIBM-7P pilot was drilled from the MaBoMo production platform to a total depth of 3,941 metres. The target area is located approximately 1.5 kilometres north-northwest...

Continue reading

Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement

Written by Customer Service on . Posted in Public Companies.

GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). As previously announced, on December 29, 2023, the Company was notified by NASDAQ that it was not in compliance with the Minimum Bid Price Requirement because the closing bid price for the Company’s American depositary shares (the...

Continue reading

AMD Accelerates Pace of Data Center AI Innovation and Leadership with Expanded AMD Instinct GPU Roadmap

Written by Customer Service on . Posted in Public Companies.

— Updated AMD Instinct accelerator roadmap brings annual cadence of leadership AI performance and memory capabilities — — New AMD Instinct MI325X accelerator expected to be available in Q4 2024 with up to 288GB of HBM3E memory; new AMD Instinct MI350 series accelerators based on AMD CDNA 4 architecture expected to be available in 2025 with 35x generational increase in AI inference performance — TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) — At Computex 2024, AMD (NASDAQ: AMD) showcased the growing momentum of the AMD Instinct™ accelerator family during the opening keynote by Chair and CEO Dr. Lisa Su. AMD unveiled a multiyear, expanded AMD Instinct accelerator roadmap which will bring an annual cadence of leadership AI performance and memory capabilities at every generation. The updated roadmap starts with the new AMD...

Continue reading

AMD Unveils Next-Gen “Zen 5” Ryzen Processors to Power Advanced AI Experiences

Written by Customer Service on . Posted in Public Companies.

Ryzen AI 300 Series AMD Ryzen AI 300 Series Processor — AMD Ryzen™ AI 300 Series Processors Unlock Transformational AI Experiences for Windows Copilot+ PCs — — AMD Ryzen™ 9000 Series Processors Set New Standards in Efficiency, Performance, and Content Creation — TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) — Today, during Computex 2024, AMD (NASDAQ: AMD) announced a groundbreaking series of next-generation architecture and products aimed at ushering in a new era of AI experiences. AMD is introducing new AMD Ryzen™ AI 300 Series processors with the world’s most powerful Neural Processing Unit (NPU)1 for next-gen AI PCs that pave the way for a future full of AI-infused computing directly on your laptop. AMD is also introducing next-gen AMD Ryzen™ 9000 Series processors for desktops, further solidifying...

Continue reading

AMD Extends AI and High-Performance Leadership in Data Center and PCs with New AMD Instinct, Ryzen and EPYC Processors at Computex 2024

Written by Customer Service on . Posted in Public Companies.

— Expanded AMD Instinct accelerator roadmap brings annual cadence of leadership AI accelerators; next generation AMD EPYC processors to extend data center CPU leadership — — New AMD Ryzen AI 300 Series laptop and AMD Ryzen 9000 Series desktop processors deliver leading performance for Copilot+ PCs, gaming, content creation and productivity — TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) — Today at the Computex 2024 opening keynote, AMD (NASDAQ: AMD) detailed new leadership CPU, NPU and GPU architectures powering end-to-end AI infrastructure from the data center to PCs. AMD unveiled an expanded AMD Instinct™ accelerator roadmap, introducing an annual cadence of leadership AI accelerators including the new AMD Instinct MI325X accelerator with industry-leading memory capacity planned to be available in Q4 2024. AMD also previewed...

Continue reading

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Written by Customer Service on . Posted in Public Companies.

Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) TACTI-004 Phase III trial will enrol approximately 750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapy Under the collaboration, Immutep will conduct the registrational TACTI-004 Phase III trial and MSD will supply KEYTRUDA Immutep retains commercial rights to efti Efti in combination with KEYTRUDA with or without chemotherapy has generated compelling efficacy and favourable safety in 1L NSCLC, one of the most relevant cancer indications with a high unmet medical need, across all levels of PD-L1 expression (negative, low, and high) SYDNEY, AUSTRALIA, June 03, 2024 (GLOBE NEWSWIRE) — Immutep...

Continue reading

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

Written by Customer Service on . Posted in Public Companies.

Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that results from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were published in Nature Medicine. Updated efficacy data in key subgroups and data on quality of life (QoL) within this publication were also presented on June 1 at the American Society of Clinical Oncology (“ASCO”) 2024 Annual Meeting. Fruquintinib is a selective oral inhibitor of vascular endothelial growth factor receptors (“VEGFRs”) 1, 2 and 3. It works as an anti-cancer therapy by blocking tumor angiogenesis,...

Continue reading

Mesoblast Corporate Presentation at Investor Conference

Written by Customer Service on . Posted in Public Companies.

NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License Application (BLA) resubmission with the United States Food and Drug Administration (FDA) for its lead product candidate Ryoncil®(remestemcel-L) in the treatment of steroid-refractory acute graft versus host disease, with potential approval in the second half of CY2024. Dr. Itescu additionally highlighted the heart failure and back pain programs in Phase 3, and the recent feedback from FDA regarding an accelerated approval pathway for the heart failure product Revascor® (rexlemestrocel). The presentation also highlighted Mesoblast’s strong United States...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.